Terapet successfully completes preclinical testing of heavy particle therapy device

We at Terapet are thrilled to announce the successful completion of preclinical testing for our innovative Qualγscan heavy particle therapy device. This achievement was made possible through our collaboration with Yonsei Cancer Hospital and Oncosoft.

The preclinical tests, conducted at Yonsei Cancer Hospital—the first in Korea to pioneer autonomous heavy particle therapy—highlight the potential of our Qualγscan device to revolutionize cancer treatment in heavy particle therapy environments. With cutting-edge facilities, including a heavy particle therapy machine and exceptional research capabilities, Yonsei Cancer Hospital was the ideal partner for this groundbreaking project.

This success is part of a bilateral innovation initiative supported by the Swiss Agency for Innovation and the Korea Institute of Industrial Technology, with funding of approximately 4.5 billion won from Korea and Switzerland. Our participation in this consortium underscores our commitment to driving forward technological advancements in cancer treatment.

At Terapet, we are proud to contribute to the future of mesoparticle therapy, which holds immense promise for cancer patients. By precisely targeting tumors with minimal impact on healthy tissue, heavy particle therapy offers hope, particularly for children and patients with cancers near critical organs.